Literature DB >> 18250951

Evidence for the effectiveness of botulinum toxin for sialorrhoea.

D D Truong1, R Bhidayasiri.   

Abstract

Sialorrhoea is a common symptom in many neurological disorders. Recently, botulinum toxin has been introduced as a treatment for sialorrhoea, and in this paper, we review the evidence for its effectiveness. The publications on the topic were searched and reviewed independently by two authors using the scale developed by the Therapeutics and Technology Assessment subcommittee for the American Academy of Neurology. All papers identified in our search fulfilled were evaluated, and classified into 1 of the 4 levels of evidence. According to this scheme, the effectiveness of botulinum toxin A in the treatment of sialorrhoea is considered established (level A). Botulinum toxin B is considered probably effective in the treatment of sialorrhoea (level B).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250951     DOI: 10.1007/s00702-007-0861-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  35 in total

1.  Botulinum toxin is a useful treatment in excessive drooling in saliva.

Authors:  K P Bhatia; A Münchau; P Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-11       Impact factor: 10.154

Review 2.  Expanding use of botulinum toxin.

Authors:  Roongroj Bhidayasiri; Daniel D Truong
Journal:  J Neurol Sci       Date:  2005-08-15       Impact factor: 3.181

3.  Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease.

Authors:  Maria Fiorella Contarino; Maurizio Pompili; Paola Tittoto; Nicola Vanacore; Mario Sabatelli; Augusto Cedrone; Gian Ludovico Rapaccini; Giovanni Gasbarrini; Pietro Attilio Tonali; Anna Rita Bentivoglio
Journal:  Parkinsonism Relat Disord       Date:  2006-06-27       Impact factor: 4.891

4.  Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands.

Authors:  K O Bushara
Journal:  Med Hypotheses       Date:  1997-04       Impact factor: 1.538

5.  Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series.

Authors:  P H Jongerius; J J Rotteveel; F van den Hoogen; F Joosten; K van Hulst; F J Gabreëls
Journal:  Eur J Pediatr       Date:  2001-08       Impact factor: 3.183

6.  Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Authors:  Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Maria Gabriella Ceravolo
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

7.  Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease.

Authors:  Okan Dogu; Demir Apaydin; Serhan Sevim; Derya Umit Talas; Mihriban Aral
Journal:  Clin Neurol Neurosurg       Date:  2004-03       Impact factor: 1.876

8.  Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.

Authors:  Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; Emilia Martignoni; Giuseppe Nappi; Claudio Pacchetti
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

9.  Botulinum toxin as an effective treatment of clozapine-induced hypersalivation.

Authors:  Kai G Kahl; Johann Hagenah; Silke Zapf; Peter Trillenberg; Christine Klein; Rebekka Lencer
Journal:  Psychopharmacology (Berl)       Date:  2004-01-28       Impact factor: 4.530

10.  Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.

Authors:  Robert Savarese; Martin Diamond; Elie Elovic; Scott R Millis
Journal:  Am J Phys Med Rehabil       Date:  2004-04       Impact factor: 2.159

View more
  2 in total

1.  IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study.

Authors:  Lejla Paracka; Katja Kollewe; Martin Klietz; Susanne Petri; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2019-07-17       Impact factor: 3.575

2.  Use of rimabotulinum toxin for focal hypertonicity management in children with cerebral palsy with nonresponse to onabotulinum toxin.

Authors:  Joline E Brandenburg; Linda E Krach; Mark E Gormley
Journal:  Am J Phys Med Rehabil       Date:  2013-10       Impact factor: 2.159

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.